Innovation for greater impact: exploring domestic resource mobilization efforts in collaboration with the Global Fund
As Aidspan has explored previously, international aid for AIDS, tuberculosis and malaria is plateauing, and a critical transition is underway to find more sustainable approaches to health financing in implementing countries.
At around 11:30 every morning, Chiku begins her work day. Carefully gathering her syringes and needles, she'll work steadily preparing doses for her clients -- all of whom wait inside her tin-roofed shack in the slum known as Nigeria: one of Nairobi, Kenya's toughest neighborhoods. The money she earns will be enough to pay her rent, and feed her own heroin habit.
Aidspan has released a brief analysis of a survey conducted of sub- and sub-sub recipients of Global Fund grants in four East Africa countries: Kenya, Rwanda, Tanzania and Uganda. All four countries are classified by the Grants Management unit as High Impact Africa 1 countries.
The Board of the Global Fund on 25 April approved renewal and interim funding of up to $310 million. These announcements do not represent additional resources but rather reflect the country allocations announced on 12 March.
I was in Nairobi recently to help Aidspan facilitate a meeting with the representatives of about 30 organizations from East and Southern Africa involved in the monitoring of global health programs.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved continued funding of up to $253.8 million for 13 applicants in a decision announced on 23 December.
The Global Fund Board has approved up to $40.5 million for four interim applicant countries: Chad, Papua New Guinea (PNG), Kenya and Mozambique. The Board decisions were based on recommendations from the Grant Approvals Committee (GAC). This brings to five the number of interim applicant countries that have received funding.
According to data compiled by the Global Fund, since the introduction of the Affordable Medicines Facility-malaria (AMFm) programme, the average cost of a course of artemisinin combination therapy (ACT) in private pharmacies has dropped by about 90% in parts of Kenya and by about 40% to 90% in Ghana, the first two countries to participate in the programme.
The Global Fund Board has approved two of the nine Round 9 proposals whose original rejection had been appealed by the applicants. The newly approved proposals are an HIV proposal from Pakistan that will cost $11.9 million and a TB proposal from Ukraine that will cost $34.6 million (costs are for the first two years). The approvals are subject to a number of requests for clarification being successfully responded to in a timely manner.